Fluidx Medical has announced that the first patient has been treated in the GPX investigational device exception (IDE) prospective multinational clinical trial.
The GPX embolic device was successfully used in a portal vein embolization procedure in preparation for hepatic resection.
“We are pleased with the complete vessel filling we observed,” said principal investigator Stephen Chen (MD Anderson Cancer Center, Houston, Texas). “GPX was easy to prepare, deliver, and use. We could see the material flow distally into the vessel segment, completely blocking blood flow to the target area. This was exactly what we were aiming for.”
The safety and effectiveness trial includes leading medical centres and investigators from the USA, Canada, and New Zealand.
“The GPX Embolic was designed without toxic solvents which can cause patient pain and require special storage, preparation, handling, and catheters to deliver,” said Russ Bjorklund, vice president, Fluidx Medical. “Clinicians need embolics that can be quickly prepared, delivered with ease, and occlude the target immediately. The GPX embolic checks these boxes making it an innovative and simple solution designed for effective vessel filling.”
